Intelligent Bio Solutions Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $7.6M
- Price
- $2.51
- % Change (Daily % change from the live per-ticker quote feed.)
- -5.28%
- Volume
- 48.6K
About
Intelligent Bio Solutions Inc. operates as a life sciences firm focused on developing non-invasive, real-time monitoring and diagnostic solutions for both patients and their primary healthcare providers. A notable product in its portfolio is the Saliva Glucose Biosensor, an organic thin-film transistor designed to precisely measure glucose levels in saliva for effective diabetes management. Beyond this, the company is actively developing a SARS-CoV-2 Biosensor, intended to serve as a supplementary diagnostic tool to existing RNA virus detection methods. It also maintains a broad biosensor platform that encompasses diverse diagnostic modalities, including biochemistry, immunology, tumor marker identification, hormone analysis, and nucleic acid diagnostics. Incorporated in 2016 and based in New York, New York, the company was formerly known as GBS Inc. before adopting its current name in October 2022. Intelligent Bio Solutions Inc. operates as a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.
Quick stats
Shares outstanding3.0M
Computed float2.4M
Float / shares78.3%
Key info
SectorHealthcare
IndustryMedical - Diagnostics & Research
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001725430
Websitehttps://ibs.inc
AI Summary
AI-generated1/17
standardbullishearnings
Intelligent Bio Solutions Reports Fiscal 2026 Full-Year Revenue Growth of 38% Year-over-Year, Driven by Reader Installed Base and High-Margin Cartridge Growth
Intelligent Bio Solutions reported fiscal 2026 revenue of $4.2 million, up 38% year-over-year, driven by a 22% expansion in its reader installed base and a 35% increase in consumable cartridges.
Gross profit margin expanded 778 basis points to 48.63%, attributed to the transition to lower-cost manufacturing partner Syrma Johari and a product mix shift toward higher-margin consumables.
The company completed all clinical data collection for its FDA 510(k) submission and remains on track for filing in the second half of calendar 2026, targeting entry into the U.S. market.
Red flags
- Net loss widened year-over-year to $12.4 million
- 1-for-10 reverse stock split effected in December 2025 indicates prior listing compliance issues
- Accumulated deficit increased to approximately $75 million